Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1616
This examiner grants 45% of resolved cases
Dongxiu Zhang Spiering examines cases in Art Unit 1616 of Tech Center 1600. She has 31 resolved cases and an allowance rate of 45.2 percent. This 45.2 percent rate suggests a prosecution process where success is achieved in less than half of the cases. The median days to allowance is 1203. This 1203-day figure is a factor for timeline expectations. Practitioners should factor this metric into their strategy in Tech Center 1600.
The interview lift is 70.9 percent. This 70.9 percent lift indicates that interviews are a tool for success. This increase suggests that direct communication can change the outcome of a case, potentially turning a rejection into a grant. With 31 resolved cases, the 45.2 percent allowance rate provides a baseline for Art Unit 1616. The 70.9 percent lift is an impactful metric in this profile. The 1203-day median is a reference point for the duration of the prosecution phase. The data highlights the role of interviewing.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18299864 | PERSONAL CLEANSING COMPOSITION FREE OF ALKYL SULFATE OR ALKYL ETHER SULFATE TYPE OF SURFACTANTS | Final Rejection | The Procter & Gamble Company |
| 18288205 | Hair Relaxer | Final Rejection | BASF SE |
| 18010220 | METHOD FOR PRODUCING A PERSONALIZED COSMETIC PREPARATION | Final Rejection | BASF SE |
| 16972220 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFOXIMINE CONTAINING SUBSTITUENTS | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18044187 | TRANSPARENT LIQUID HAIR MASK WITH CONSISTENCY TRANSFORMATION AND IMMEDIATE EFFECT DURING APPLICATION | Non-Final OA | Henkel AG & Co. KGaA |
| 18021841 | MICROCAPSULE WITH ACETAMIDES AND DIFLUFENICAN | Final Rejection | MONSANTO TECHNOLOGY LLC |
| 18857424 | POLYSULFIDE MICROPARTICLES AND USES THEREOF | Non-Final OA | Vanderbilt University |
| 18251509 | AGROCHEMICAL COMPOSITION WITH IMPROVED DRIFT, SPREADING AND UPTAKE PROPERTIES | Non-Final OA | Bayer Aktiengesellschaft |
| 18627155 | COMPOSITIONS AND METHODS FOR REDUCING ADVERSE EFFECTS OF STORAGE, TRANSPORT AND ADMINISTRATION OF ANTIGEN-CONTAINING FORMULATIONS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 17757168 | STABLE COMPOSITION COMPRISING COMBINATION OF SPECIFIC INGREDIENTS | Final Rejection | L'OREAL |
| 17793611 | METHOD OF PRODUCING CAPSULE COMPRISING PANCREATIC ISLET | Non-Final OA | OTSUKA PHARMACEUTICAL FACTORY, INC. |
| 18294890 | OIL-IN-WATER EMULSION COSMETIC | Final Rejection | SHISEIDO COMPANY, LTD. |
| 18043559 | COSMETIC | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 18566724 | COSMETIC CONCENTRATE IN THE FORM OF A FILM | Non-Final OA | BEIERSDORF AG |
| 18689307 | IMPROVED PERFUME COMPOSITIONS COMPRISING SULFUR-CONTAINING PRO-FRAGRANCE COMPOUNDS | Non-Final OA | Firmenich SA |
| 18570401 | NOVALURON SOLID COMPOSITION | Non-Final OA | Adama Makhteshim Ltd. |
| 18255502 | DITHIOCARBAMATE FUNGICIDE COMPOSITION | Non-Final OA | Adama Makhteshim Ltd. |
| 18041648 | A LIQUID AGROCHEMICAL COMPOSITION | Non-Final OA | UPL Europe LTD |
| 18159806 | SOLID DISPERSION FOR THERAPEUTIC USE | Non-Final OA | FLORIDA RESEARCH GROUP LLC |
| 18421666 | EX-VIVO CULTURE SYSTEM AND METHODS OF USING SAME | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 17785959 | Personal Lubricant Composition | Non-Final OA | Reckitt Benckiser Health Limited |
| 18745813 | BACILLUS VELEZENSIS DRY SUSPENDING AGENT AND PREPARATION METHOD THEREOF | Non-Final OA | GUANGDONG BRANCH OF CHINA TOBACCO GEN. CO., LTD. |
| 18016693 | METHOD OF MAKING FUNCTIONAL FIBER HAVING IMPROVED DEWATERING EFFICIENCY | Non-Final OA | CORN PRODUCTS DEVELOPMENT, INC |
| 17609042 | GEL-TYPE SKIN EXTERNAL COMPOSITION | Final Rejection | NAGASE VIITA CO., LTD. |
| 18019505 | ESKETAMINE-SUSPENSION-TTS | Non-Final OA | LTS LOHMANN THERAPIE-SYSTEME AG |
| 17786223 | TRANSMUCOSAL THERAPEUTIC SYSTEM CONTAINING AGOMELATINE | Final Rejection | LTS LOHMANN Therapie-Systeme AG |
| 18247527 | Composition for Treating Hair and Skin | Non-Final OA | DR. KURT WOLFF GMBH & CO. KG |
| 18001343 | IMPROVED VIRUCIDAL FORMULATIONS | Final Rejection | FIREBRICK PHARMA LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy